According to the newspaper, the US Health and Human Services Department said on Saturday that the Emergent BioSolutions facility will now only be manufacturing the Johnson & Johnson vaccine to avoid future mix-ups.
Several major countries including Canada, France, and Germany, have also limited use of Astra's vaccine while they investigate reports of blood clotting, although the reports are incredibly rare.
The facility had been working to produce ingredients for both the Johnson & Johnson and AstraZeneca vaccines and had mixed up ingredients from the two vaccines, according to The New York Times and The Washington Post.
Had this portion of ingredients been approved it would have contributed to vaccine production.
Vehicle rams Capitol barricade, injuring 2 officers; driver shot dead
Little is known about the suspect or possible motive, authorities said, as the investigation remains in its early stage. Pelosi ordered the flags at the Capitol to be flown at half-staff in honor of the deceased Capitol Police officer.
"The COVID-19 pandemic has had a profound impact on adolescents, not just with the complications of the disease, but with their education, mental health, and wellbeing", said Paul Stoffels, vice chairman of the executive committee and chief scientific officer at Johnson & Johnson, in a statement Friday.
Unlike Johnson & Johnson, AstraZeneca does not yet have emergency authorization from the Food and Drug Administration for its vaccine.
The top United States infectious disease doctor told Reuters on Thursday that the country may not need AstraZeneca's vaccine, even if it wins approval. The mistake happened weeks ago, and none of the doses were distributed. "This batch was never advanced to the filling and finishing stages of our manufacturing process", the vaccine manufacturer said. Moreover, the contamination is a point of corporate embarrassment for both Johnson & Johnson and Emergent, after both lobbied the government for vaccine production contracts.
Emergent said the quality control systems in place worked as planned and it will continue to work toward FDA approval. The Johnson & Johnson vaccine is administered in one dose, AstraZeneca's in two doses. Both actions came after a New York Times investigation into how the company had gained outsize influence over the repository.